The role of docetaxel in gastric cancer

Wagner, 2005, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 2, CD004064 Sulkes, 1994, Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group, Br J Cancer, 70, 380, 10.1038/bjc.1994.310 Einzig, 1996, Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293, Med Oncol, 13, 87, 10.1007/BF02993858 Taguchi, 1998, Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A), Gan To Kagaku Ryoho, 25, 1915 Mai, 1999, A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B), Gan To Kagaku Ryoho, 26, 487 Vanhoefer, 1999, Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer, Proc Am Soc Clin Oncol Graziano, 2000, A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer, Ann Oncol, 11, 1263, 10.1023/A:1008373814453 Mavroudis, 2000, Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial, Am J Clin Oncol, 23, 341, 10.1097/00000421-200008000-00005 Bang, 2002, Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial, Jpn J Clin Oncol, 32, 248, 10.1093/jjco/hyf057 Giuliani, 2003, Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M), Anticancer Res, 23, 4219 Lee, 2005, Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy, J Clin Oncol, 22, 4220, 10.1200/jco.2005.23.16_suppl.4220 Roth, 2000, Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO), Ann Oncol, 11, 301, 10.1023/A:1008342013224 Roth, 2004, 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docctaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II triai, Ann Oncol, 15, 759, 10.1093/annonc/mdh187 Roth, 2004, Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical cancer research (SAKK), J Clin Oncol, 22, 4020, 10.1200/jco.2004.22.14_suppl.4020 Ajani, 2005, Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma, J Clin Oncol, 23, 5660, 10.1200/JCO.2005.17.376 Van Cutsem, 2006, Docetaxel-cisplatin-5-fluorouracil as first-line therapy for advanced gastric cancer: a multicenter, randomized phase III study, J Clin Oncol, 10.1200/JCO.2006.06.8429 Moiseyenko, 2005, Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) in patients (pts) with metastatic gastric adenocarcinoma, J Clin Oncol, 23, 4002, 10.1200/jco.2005.23.16_suppl.4002 Moiseyenko V, Van Cutsem E, Tjulandin S, et al. Adding docetaxel to cisplatin-5-fluorouracil improves quality of life in advanced gastric cancer: a phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15–18 June 2005 (Abstract O-013). Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Docetaxel when added to cisplatin-5-fluorouracil improves survival in advanced gastric cancer: a phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15–18 June 2005 (Abstract O-012). Lacave, 1991, Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial, Ann Oncol, 2, 751, 10.1093/oxfordjournals.annonc.a057858 Kim, 1993, A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer, Cancer, 71, 3813, 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5 Rougier, 1994, Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis, Eur J Cancer, 30A, 1263, 10.1016/0959-8049(94)90170-8 Vanhoefer, 2000, J Clin Oncol, 18, 2648, 10.1200/JCO.2000.18.14.2648 Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130 Ross, 2002, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer, J Clin Oncol, 20, 1996, 10.1200/JCO.2002.08.105 Webb, 1997, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer, J Clin Oncol, 15, 261, 10.1016/S0959-8049(97)86090-X Aapro, 2006, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, Eur J Cancer, 10.1016/j.ejca.2006.05.002 National Comprehensive Cancer Network Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 24, 3187, 10.1200/JCO.2006.06.4451 Kim, 1999, Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma, Cancer, 85, 295, 10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H Kollmannsberger, 2000, A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer, Br J Cancer, 83, 458, 10.1054/bjoc.2000.1295